The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Amedisys Inc (NASDAQ: AMED) closed the day trading at $97.89 up 0.39% from the previous closing price of $97.51. In other words, the price has increased by $0.39 from its previous closing price. On the day, 0.41 million shares were traded. AMED stock price reached its highest trading level at $97.945 during the session, while it also had its lowest trading level at $97.36.
Ratios:
For a better understanding of AMED, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.64. For the most recent quarter (mrq), Quick Ratio is recorded 1.29 and its Current Ratio is at 1.29. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.32.
Truist Downgraded its Buy to Hold on June 07, 2023, while the target price for the stock was maintained at $97.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 08 ’25 when Guidroz Allyson sold 374 shares for $96.00 per share. The transaction valued at 35,904 led to the insider holds 8,114 shares of the business.
Guidroz Allyson bought 374 shares of AMED for $35,853 on May 08 ’25. On Mar 04 ’25, another insider, Guidroz Allyson, who serves as the Chief Accounting Officer of the company, sold 2,041 shares for $92.03 each. As a result, the insider received 187,833 and left with 8,761 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMED now has a Market Capitalization of 3212710656 and an Enterprise Value of 3425294336. As of this moment, Amedisys’s Price-to-Earnings (P/E) ratio for their current fiscal year is 36.23, and their Forward P/E ratio for the next fiscal year is 19.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.35 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 1.444 whereas that against EBITDA is 14.033.
Stock Price History:
The Beta on a monthly basis for AMED is 0.94, which has changed by 0.06866813 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, AMED has reached a high of $98.95, while it has fallen to a 52-week low of $82.15. The 50-Day Moving Average of the stock is 3.73%, while the 200-Day Moving Average is calculated to be 5.09%.
Shares Statistics:
Over the past 3-months, AMED traded about 368.04K shares per day on average, while over the past 10 days, AMED traded about 419720 shares per day. A total of 32.82M shares are outstanding, with a floating share count of 31.92M. Insiders hold about 2.75% of the company’s shares, while institutions hold 90.91% stake in the company. Shares short for AMED as of 1748563200 were 1878352 with a Short Ratio of 5.10, compared to 1745971200 on 2481772. Therefore, it implies a Short% of Shares Outstanding of 1878352 and a Short% of Float of 5.82.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
